Law firm Wisner Baum is currently representing patients in lawsuits against the makers of Risperdal, Invega, and Zyprexa. The core allegation centers on the claim that pharmaceutical companies intentionally downplayed the relationship between prolactin-elevating drugs and breast cancer to protect market interests. Plaintiffs argue that both patients and their physicians were denied critical information necessary for informed medical consent.

Scientific Data and Health Disparities

The scientific foundation for these claims rests on a growing body of research. A 2022 observational study of over 540,000 U.S. women indicated a 62% higher relative risk of invasive breast cancer among those taking highly prolactin-elevating antipsychotics. Furthermore, a 2024 Swedish study found that the incidence of breast cancer was 47% higher in women who had taken such medications for five years or longer. Beyond the physiological link, systemic disparities persist; a 2026 review published in Schizophrenia Bulletin confirmed that women with severe mental illness are significantly less likely to participate in cancer screenings and experience higher mortality rates when diagnosed.

Monique Alarcon, a partner at Wisner Baum, asserts that the medical community has failed to reconcile long-standing research with clinical practice. While manufacturers have previously faced multi-billion dollar settlements for off-label marketing and other misconduct, these new complaints seek to hold companies accountable for failing to disclose specific carcinogenic risks. The litigation aims to determine whether clinicians were sufficiently warned to monitor patients effectively or if the omission of these dangers has left a vulnerable population without adequate protection.